NEW YORK (GenomeWeb News) – Becton Dickinson said today that its fiscal second-quarter revenues rose nearly 4 percent year over year, beating analyst estimates.

For the quarter ended March 31, 2012, BD posted $1.99 billion in revenues, up from $1.92 billion for the second quarter of 2011, outpacing analysts' consensus estimate of $1.94 billion.

Revenue from the firm's BD Diagnostics segment was up 4 percent to $630 million, compared to $605 million a year ago. Growth was driven primarily by the preanalytical systems unit and women's health and cancer, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.